[SFGate] Gilead hepatitis C pill reaches $3.48 billion in quarterly sales

“The fundamental concern is Sovaldi and other speciality drugs are going to put an unsustainable burden on the health insurance system,” said John Rother, CEO of the National Coalition on Health Care, which lobbies for health-system reform. In a poll it conducted this month of 2,000 people, nearly 60 percent said they were concerned about affording specialty drugs in the future should they need them.

Read More


Sign-up for updates

  • This field is for validation purposes and should be left unchanged.